- Trial averages describe groups under defined regimens and follow-up periods.
- STEP 1 and SURMOUNT-1 reported different named regimens, populations and dose groups.
- The study results are not personal forecasts.
- Neither study evaluated a Kind MD compounded preparation.
- Individual results vary, and a licensed provider can discuss the evidence in context.
What does a study average mean?
Trial averages describe groups under a named regimen, population, comparator and follow-up period. They are not a personal result and are not a prediction for a compounded preparation.
When you see a percentage, look for the study name, the regimen, the comparison group and the follow-up period. Those details tell you what was measured and what the number cannot answer.
STEP 1: semaglutide study context
STEP 1 (PubMed 33567185) studied semaglutide 2.4 mg weekly in 1,961 adults for 68 weeks and reported -14.9% vs -2.4% placebo. Neither STEP 1 nor SURMOUNT-1 evaluated a Kind MD compounded preparation; the results do not apply directly to a compounded preparation, and individual results vary.
That result belongs to the named STEP 1 study regimen, population and follow-up period. Neither STEP 1 nor this article turns the group average into an individual forecast.
SURMOUNT-1: tirzepatide study context
SURMOUNT-1 (PubMed 35658024) studied tirzepatide 5/10/15 mg weekly in 2,539 adults for 72 weeks and reported -15.0/-19.5/-20.9% vs -3.1% placebo. Neither STEP 1 nor SURMOUNT-1 evaluated a Kind MD compounded preparation; the results do not apply directly to a compounded preparation, and individual results vary.
These are the reported group results for the named study dose groups. They should not be presented as a single result for every person or product.
Why the numbers do not predict one person
Study populations, protocols and follow-up periods differ. A person’s health history, other medicines, prescribed product and response can also differ from the study context. The evidence answers the question the study asked; it does not answer every personal treatment question.
Neither study evaluated a Kind MD compounded preparation. The results do not apply directly to a compounded preparation, and individual results vary.
The safest reading is narrow: use the named trial to understand what was measured, then bring personal questions to a licensed healthcare provider.
Questions for a provider
- Which study context is most relevant to the question I am asking?
- How does my prescription differ from the named study regimen?
- Which personal factors should we consider before interpreting a group result?
- What should I track or discuss at follow-up?
- Which questions belong with the dispensing pharmacy?
A licensed healthcare provider makes an independent prescribing decision when clinically appropriate.
